These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 19218011

  • 21. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
    Armour KL, Smith CS, Clark MR.
    J Immunol Methods; 2010 Mar 31; 354(1-2):20-33. PubMed ID: 20138184
    [Abstract] [Full Text] [Related]

  • 22. Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation.
    Golay J, Valgardsdottir R, Musaraj G, Giupponi D, Spinelli O, Introna M.
    Blood; 2019 Mar 28; 133(13):1395-1405. PubMed ID: 30655272
    [Abstract] [Full Text] [Related]

  • 23. Differential role of neutrophil Fcgamma receptor IIIB (CD16) in phagocytosis, bacterial killing, and responses to immune complexes.
    Fossati G, Moots RJ, Bucknall RC, Edwards SW.
    Arthritis Rheum; 2002 May 28; 46(5):1351-61. PubMed ID: 12115243
    [Abstract] [Full Text] [Related]

  • 24. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
    Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K.
    Clin Cancer Res; 2005 Mar 15; 11(6):2327-36. PubMed ID: 15788684
    [Abstract] [Full Text] [Related]

  • 25. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K, Kato K, Satoh M.
    Glycobiology; 2009 Feb 15; 19(2):126-34. PubMed ID: 18952826
    [Abstract] [Full Text] [Related]

  • 26. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G.
    Cancer Res; 2004 Jul 01; 64(13):4664-9. PubMed ID: 15231679
    [Abstract] [Full Text] [Related]

  • 27. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.
    Cancer Res; 2008 Oct 01; 68(19):8049-57. PubMed ID: 18829563
    [Abstract] [Full Text] [Related]

  • 28. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ.
    Arthritis Rheum; 2003 Feb 01; 48(2):455-9. PubMed ID: 12571855
    [Abstract] [Full Text] [Related]

  • 29. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.
    Leuk Res; 2006 May 01; 30(5):625-31. PubMed ID: 16289746
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
    Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Passmore D, Chen TH, Chen S, Liu J, Kuhne MR, Srinivasan M, Assad A, Witte A, Graziano RF, King DJ.
    Clin Cancer Res; 2009 May 15; 15(10):3376-83. PubMed ID: 19401346
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y, Yagi H, Satoh T, Shibata-Koyama M, Masuda K, Satoh M, Kato K, Iida S.
    PLoS One; 2015 May 15; 10(10):e0140120. PubMed ID: 26444434
    [Abstract] [Full Text] [Related]

  • 34. NA1/NA2 antisera inhibit FcgammaRI- but not FcgammaRII- mediated phagocytosis.
    Flesch BK, Maass W, Neppert J.
    Vox Sang; 1998 May 15; 75(3):247-52. PubMed ID: 9852415
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effects of leukocyte inhibitory factor (LIF) on neutrophil phagocytosis and bactericidal activity.
    Borish L, Rocklin RE.
    J Immunol; 1987 Mar 01; 138(5):1475-9. PubMed ID: 2949016
    [Abstract] [Full Text] [Related]

  • 37. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
    Lefebvre ML, Krause SW, Salcedo M, Nardin A.
    J Immunother; 2006 Mar 01; 29(4):388-97. PubMed ID: 16799334
    [Abstract] [Full Text] [Related]

  • 38. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
    Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, Guo Y.
    Cancer Res; 2008 Apr 01; 68(7):2400-8. PubMed ID: 18381448
    [Abstract] [Full Text] [Related]

  • 39. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
    Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK.
    Front Immunol; 2018 Apr 01; 9():3124. PubMed ID: 30761158
    [Abstract] [Full Text] [Related]

  • 40. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
    Mineo JF, Scheffer A, Karkoutly C, Nouvel L, Kerdraon O, Trauet J, Bordron A, Dessaint JP, Labalette M, Berthou C, Labalette P.
    Invest Ophthalmol Vis Sci; 2008 Nov 01; 49(11):4738-45. PubMed ID: 18552383
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.